A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Innoviva, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 12,600 shares of INVA stock, worth $241,289. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,600
Previous 20,000 37.0%
Holding current value
$241,289
Previous $328,000 25.91%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$16.33 - $20.04 $6.32 Million - $7.76 Million
387,005 Added 377.75%
489,455 $9.45 Million
Q2 2024

Aug 14, 2024

BUY
$14.4 - $16.4 $378,187 - $430,713
26,263 Added 34.47%
102,450 $1.68 Million
Q1 2024

May 15, 2024

SELL
$14.56 - $16.78 $2.99 Million - $3.45 Million
-205,617 Reduced 72.96%
76,187 $1.16 Million
Q4 2023

Feb 14, 2024

BUY
$12.32 - $16.27 $1.24 Million - $1.63 Million
100,256 Added 55.22%
281,804 $4.52 Million
Q3 2023

Nov 14, 2023

SELL
$12.37 - $13.89 $6.81 Million - $7.65 Million
-550,859 Reduced 75.21%
181,548 $2.36 Million
Q2 2023

Aug 14, 2023

SELL
$11.39 - $13.72 $1.32 Million - $1.59 Million
-116,220 Reduced 13.7%
732,407 $9.32 Million
Q1 2023

May 15, 2023

SELL
$10.73 - $13.6 $1.47 Million - $1.86 Million
-136,912 Reduced 13.89%
848,627 $9.55 Million
Q4 2022

Feb 14, 2023

BUY
$11.8 - $13.78 $1.74 Million - $2.03 Million
147,595 Added 17.61%
985,539 $13.1 Million
Q3 2022

Nov 14, 2022

BUY
$11.61 - $15.22 $2.76 Million - $3.62 Million
237,602 Added 39.58%
837,944 $9.73 Million
Q2 2022

Aug 15, 2022

BUY
$14.32 - $19.88 $2.08 Million - $2.89 Million
145,364 Added 31.95%
600,342 $8.86 Million
Q1 2022

May 16, 2022

BUY
$15.39 - $20.25 $6.47 Million - $8.52 Million
420,636 Added 1224.84%
454,978 $8.8 Million
Q4 2021

Feb 14, 2022

SELL
$15.91 - $18.72 $5.67 Million - $6.67 Million
-356,537 Reduced 91.21%
34,342 $592,000
Q3 2021

Nov 15, 2021

BUY
$13.06 - $17.24 $2.19 Million - $2.9 Million
168,057 Added 75.42%
390,879 $6.53 Million
Q2 2021

Aug 16, 2021

SELL
$11.45 - $13.96 $677,885 - $826,487
-59,204 Reduced 20.99%
222,822 $2.99 Million
Q1 2021

May 17, 2021

BUY
$11.06 - $12.87 $56,240 - $65,443
5,085 Added 1.84%
282,026 $3.37 Million
Q4 2020

Feb 16, 2021

SELL
$9.33 - $12.48 $841,108 - $1.13 Million
-90,151 Reduced 24.56%
276,941 $3.43 Million
Q3 2020

Nov 16, 2020

BUY
$10.33 - $14.49 $1.29 Million - $1.81 Million
124,689 Added 51.44%
367,092 $3.84 Million
Q2 2020

Aug 14, 2020

SELL
$11.49 - $15.26 $5.48 Million - $7.28 Million
-477,337 Reduced 66.32%
242,403 $3.39 Million
Q1 2020

May 15, 2020

BUY
$8.11 - $15.23 $1.04 Million - $1.94 Million
127,653 Added 21.56%
719,740 $8.46 Million
Q4 2019

Feb 14, 2020

SELL
$10.28 - $14.38 $2.39 Million - $3.34 Million
-232,596 Reduced 28.2%
592,087 $8.38 Million
Q3 2019

Nov 14, 2019

BUY
$10.05 - $14.55 $5.21 Million - $7.54 Million
517,911 Added 168.83%
824,683 $8.69 Million
Q2 2019

Aug 14, 2019

BUY
$13.1 - $14.95 $66,286 - $75,647
5,060 Added 1.68%
306,772 $4.47 Million
Q1 2019

May 15, 2019

BUY
$13.69 - $20.06 $2.18 Million - $3.19 Million
159,016 Added 111.44%
301,712 $0
Q4 2018

Feb 14, 2019

BUY
$13.96 - $18.26 $1.8 Million - $2.35 Million
128,797 Added 926.66%
142,696 $2.49 Million
Q2 2018

Aug 10, 2018

BUY
$13.44 - $17.59 $16,746 - $21,917
1,246 Added 9.85%
13,899 $0
Q1 2018

May 11, 2018

SELL
$13.8 - $16.99 $106,839 - $131,536
-7,742 Reduced 37.96%
12,653 $211,000
Q4 2017

Feb 09, 2018

SELL
$11.73 - $14.75 $1.64 Million - $2.07 Million
-140,061 Reduced 87.29%
20,395 $289,000
Q3 2017

Nov 09, 2017

BUY
$12.06 - $14.12 $1.94 Million - $2.27 Million
160,456
160,456 $2.27 Million

Others Institutions Holding INVA

About Innoviva, Inc.


  • Ticker INVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,706,000
  • Market Cap $1.33B
  • Description
  • Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...
More about INVA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.